Argenica Clears Final FDA Safety Hurdle for ARG-007, Eyes Phase 2b Trial Start
Argenica has completed the last FDA-mandated cardiac safety assay for its stroke drug ARG-007, paving the way to lift the clinical hold and initiate Phase 2b trials in the US.
- ARG-007 shows no cardiac hERG channel inhibition
- All three FDA safety assays completed with clean profiles
- Phase 2b trial protocol nearing finalisation
- Comprehensive FDA clinical hold response imminent
- Potential US trial commencement pending FDA approval
Final FDA Cardiac Safety Test Passed for ARG-007
Argenica Therapeutics (ASX:AGN) has ticked off the last of three critical FDA safety studies for its lead neuroprotective drug ARG-007 (xaranetide). The company announced successful completion of a GLP-compliant in vitro hERG assay, showing no significant inhibition of the cardiac potassium channel that is often linked to dangerous arrhythmias. This result directly addresses the FDA’s previous clinical hold concerns related to cardiac safety.
The hERG channel plays a central role in maintaining normal heart rhythm, and drug-induced inhibition has historically led to market withdrawals due to sudden cardiac death risks. At the highest test concentration, ARG-007 maintained essentially 100% of baseline channel activity, signalling a very low cardiac liability. The assay was conducted under rigorous conditions consistent with FDA guidelines by B'SYS GmbH in Switzerland.
Completing the Safety Triad to Unlock Clinical Progress
This hERG assay completes the trio of FDA-requested safety studies, following earlier clearances of the TNK and genotoxicity assays. With all three demonstrating clean and favourable safety profiles, Argenica is positioned to submit a comprehensive response to the FDA’s clinical hold. The company expects to finalise the Phase 2b trial protocol in the coming weeks, focusing on moderate to severe acute ischaemic stroke patients.
Once the FDA accepts this submission and lifts the clinical hold, Argenica can reinstate the Investigational New Drug (IND) application and commence US clinical trials. This is a pivotal step for ARG-007, which aims to reduce brain tissue death and improve recovery outcomes after stroke.
Next Steps Toward Phase 2b Trial Initiation
Managing Director Dr Liz Dallimore highlighted the significance of the hERG assay milestone, noting it was the FDA’s specific deficiency preventing clinical progression. The clean, GLP-compliant result removes a major regulatory barrier. Argenica plans to submit the full clinical hold response shortly, incorporating the updated Phase 2b protocol and investigational brochure.
Assuming FDA approval, this would unlock the path to Phase 2b trials in the US, complementing ongoing preparations for trials in Australia. This progress follows a series of regulatory wins and trial design advancements earlier in 2026, including successful genotoxicity testing and AI-enabled patient selection strategies.
Bottom Line?
Argenica’s cleared cardiac safety hurdle brings ARG-007 closer to US trials, but FDA’s final review remains the key gatekeeper.
Questions in the middle?
- How quickly will the FDA review and respond to Argenica’s comprehensive clinical hold submission?
- Will the Phase 2b protocol finalisation incorporate any additional safety or efficacy measures?
- How will Argenica balance US and Australian trial timelines and regulatory requirements moving forward?
